Literature DB >> 626494

In vitro activity of antimicrobial agents on Legionnaires disease bacterium.

C Thornsberry, C N Baker, L A Kirven.   

Abstract

Six isolates of Legionnaires disease bacteria were tested for their susceptibility to 22 antimicrobial agents. The most active agent was rifampin (minimal inhibitory concentration, </=0.01 mug/ml). On the basis of minimal inhibitory concentration breakpoints that have been used to categorize susceptibility for most of these drugs, the organisms were susceptible to rifampin, cefoxitin, erythromycin, the aminoglycosides, minocycline and doxycycline, chloramphenicol, ampicillin, penicillin G, carbenicillin, colistin, and sulfamethoxazole-trimethoprim (19:1 ratio); sensitive to intermediate in susceptibility to tetracycline, methicillin, cefamandole, cephalothin, and clindamycin; and resistant to vancomycin. More clinical data must be obtained before an optimal therapeutic regimen can be recommended.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 626494      PMCID: PMC352188          DOI: 10.1128/AAC.13.1.78

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  2 in total

1.  Laboratory evaluation of a rapid, automatic susceptibility testing system: report of a collaborative study.

Authors:  C Thornsberry; T L Gavan; J C Sherris; A Balows; J M Matsen; L D Sabath; F Schoenknecht; L D Thrupp; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1975-04       Impact factor: 5.191

2.  Activity of minocycline against Acinetobacter calcoaceticus var. anitratus (syn. Herellea vaginicola) and Serratia marcescens.

Authors:  E G Maderazo; R Quintiliani; R C Tilton; R Bartlett; N C Joyce; V T Andriole
Journal:  Antimicrob Agents Chemother       Date:  1975-07       Impact factor: 5.191

  2 in total
  19 in total

1.  Intraocular penetration of rifampin after oral administration.

Authors:  K W Wong; D J D'Amico; B S Oum; P A Baker; K R Kenyon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

2.  Legionnaires' disease.

Authors:  J Righter; M Bentley-Taylor
Journal:  Can Med Assoc J       Date:  1979-05-05       Impact factor: 8.262

3.  Intracellular multiplication of Legionnaires' disease bacteria (Legionella pneumophila) in human monocytes is reversibly inhibited by erythromycin and rifampin.

Authors:  M A Horwitz; S C Silverstein
Journal:  J Clin Invest       Date:  1983-01       Impact factor: 14.808

4.  Inoculum standardization in antimicrobial susceptibility testing: evaluation of overnight agar cultures and the Rapid Inoculum Standardization System.

Authors:  C N Baker; C Thornsberry; R W Hawkinson
Journal:  J Clin Microbiol       Date:  1983-03       Impact factor: 5.948

Review 5.  Legionellosis.

Authors:  J A Blackmon; F W Chandler; W B Cherry; A C England; J C Feeley; M D Hicklin; R M McKinney; H W Wilkinson
Journal:  Am J Pathol       Date:  1981-06       Impact factor: 4.307

6.  Characteristics of environmental isolates of Legionella pneumophila.

Authors:  L H Orrison; W B Cherry; C B Fliermans; S B Dees; L K McDougal; D J Dodd
Journal:  Appl Environ Microbiol       Date:  1981-07       Impact factor: 4.792

7.  Isolation of Legionella spp. from environmental water samples by low-pH treatment and use of a selective medium.

Authors:  C A Bopp; J W Sumner; G K Morris; J G Wells
Journal:  J Clin Microbiol       Date:  1981-04       Impact factor: 5.948

8.  A plasmid in Legionella pneumophila.

Authors:  G B Knudson; P Mikesell
Journal:  Infect Immun       Date:  1980-09       Impact factor: 3.441

Review 9.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

10.  Inactivation of beta-lactam antibiotics by Legionella pneumophila.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.